BenzingaAugust 7, 2026 at 9:14 AM NY2 Months Ago
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
